Satellos to Participate in Upcoming Investor Conferences
Globe Newswire•21/10/2026•07:00 ET
0
Key Highlights
- ➤Satellos (MSLE) management to participate in two November investor conferences
- ➤Guggenheim fireside chat scheduled for Nov. 9 at 9:30 a.m. ET
- ➤Forazapadin is being evaluated in two Phase 2 DMD trials
- ➤Phase 2 FSHD trial expected to begin in fourth quarter of 2026
TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that management will participate in the following investor conferences in November.
Guggenheim 3rd Annual Healthcare Innovation Conference Date: Monday, Nov. 9, 2026 Fireside Chat: 9:30 a.m. ET Location: Boston, MA Webcast
Get started
Create a free account to read the full story.